Table 1.
Summary of SBRT studies.
| Author | Primary tumor | Number of patients | Median followup | Dose (median) | Outcomes | Toxicity |
|---|---|---|---|---|---|---|
| Le et al. [16] | Lung (91%), sarcoma (6%), and HCC (3%) | 12 | 18 mo. | 15–25 Gy in 1 fraction | LC at 15–20 Gy: 67% LC at 25 Gy: 56% 1 yr OS: 56% |
19% pneumothorax (associated with fiducial placement) |
| Schefter et al. [19] | Colorectal (23.7%), sarcoma (18.4%), RCC (18.4%), lung (13.2%), and other (26.4%) | 38 | 15.4 mo. | 48–60 Gy in 3 fractions | 1 yr LC: 100% 2 yr LC: 96% 2 yr OS: 39% |
No ≥ G4 toxicity G3 toxicity: 8% |
| Wulf et al. [20] | Lung (45%), breast (10%), colon (8%), kidney (8%), sarcoma (8%), and other (18%) | 25 | 14 mo. | 26 Gy in 1 fraction | LC: 100% 1 yr OS: 68% |
No ≥ G3 toxicity |
| Dhakal et al. [21] | Sarcoma (100%) | 52 | 10.8 mo. | 50 Gy in 5 fractions | 2 yr LC: 88% 3 yr LC: 82% MS: 2/1 yrs |
No ≥ G3 toxicity |
| Mehta et al. [22] | Sarcoma (100%) | 16 | 20 mo. | 54 Gy in 3-4 fractions | 43 mo. LC: 94% 4 yr OS: 72% |
No ≥ G2 toxicity |
| Ricardi et al. [23] | Lung (55.7%), colorectal (21.3%), pancreas (3.4%), HCC (3.4%), head and neck (3.4%), sarcoma (1.6%), and other (11.2%) | 61 | 20.4 mo. | 26 Gy in 1 fraction | 2 yr LC: 89% 3 yr LC: 83.5% 2 yr OS: 66.5% 3 yr OS: 52.5% |
G3 toxicity: 1.6% |